Emerging Market ADRs Beat U.S. Stocks

NEW YORK (TheStreet) -- It has been a roller-coaster ride for the S&P 500 during the last week, falling one day and gaining on the other. The index has lost 1.4% during the past week, followed by a 0.8% drop in Dow Jones and a 0.2% decline in India's Nifty Index. Among other emerging markets, Shanghai Composite Index gained 0.6% while Brazil's Bovespa inched up 0.2%.

We list a few ADRs that have outperformed both the U.S. and domestic markets during this period.

Synutra International(SYUT) gained 18% during the last week. The company is a China-based producer, marketer and seller of nutritional products for infants, children and adults. As of March 31, 2010, the company's network is comprised of more than 540 independent distributors and more than 1,000 independent sub-distributors who sell its products in more than 71,000 retail outlets.

On June 10, the company reported its results for the fourth quarter and full year 2010. Net sales during the fourth quarter increased 13.4% to $82.4 million, while the company swung to a net profit of 17 cents per share compared to a loss in the same period a year ago.

Oppenheimer & Co. rated the stock a buy with a price target of $27, implying an 11% upside above current levels.

A-Power Energy Generation(APWR) gained 17.7% during the past week. The company is engaged in providing onsite distributed power generation systems and micro power grids for industrial companies, primarily in the Peoples Republic of China and Southeast Asia.

The stock rose on the back of first-quarter 2010 results, which were released yesterday. Revenues jumped 115.8% year-over-year to $67.3 million. Net income soared to 66 cents per share from 4 cents per share a year ago, while cash and cash equivalents increased to $220.4 million from $179.8 million at Dec. 31, 2009.

The company raised its outlook that revenue for 2010 will reach $500 million and net income will reach $60 million, from previously announced annual guidance of $380 million in revenues and $45 million in net income.

Oppenheimer & Co. rated the stock a buy with price target of $15, implying a 64% upside over current levels.